BusinessCocrystal Pharma Receives FDA Clearance to Initiate Phase 2a Clinical Study Evaluating CC-31244 for the Treatment of Hepatitis C VirusBy Nasdaq OMXApr 3, 2018, 12:01 PM UTC
BusinessCocrystal Pharma Reports 2017 Financial Results and Provides Corporate Overview and Business OutlookBy Nasdaq OMXMar 22, 2018, 11:05 AM UTC
BusinessCocrystal Pharma Announces Uplist to The Nasdaq Capital MarketBy Nasdaq OMXMar 12, 2018, 12:30 PM UTC
BusinessCocrystal Pharma Provides Update on Reverse Stock SplitBy Nasdaq OMXJan 23, 2018, 9:30 PM UTC
BusinessCocrystal Pharma Announces 1-for-30 Reverse Stock SplitBy Nasdaq OMXJan 23, 2018, 2:15 PM UTC
BusinessCocrystal Pharma Announces Filing 2017 Third Quarter Financial Statements and Provides Company UpdateBy Nasdaq OMXNov 8, 2017, 10:30 PM UTC
